Literature DB >> 20859676

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

Sean D McAllister1, Ryuichi Murase, Rigel T Christian, Darryl Lau, Anne J Zielinski, Juanita Allison, Carolina Almanza, Arash Pakdel, Jasmine Lee, Chandani Limbad, Yong Liu, Robert J Debs, Dan H Moore, Pierre-Yves Desprez.   

Abstract

Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Therefore, effective, targeted, and non-toxic therapies are urgently required. Id-1, an inhibitor of basic helix-loop-helix transcription factors, has recently been shown to be a key regulator of the metastatic potential of breast and additional cancers. We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, down-regulated Id-1 gene expression in aggressive human breast cancer cells in culture. Using cell proliferation and invasion assays, cell flow cytometry to examine cell cycle and the formation of reactive oxygen species, and Western analysis, we determined pathways leading to the down-regulation of Id-1 expression by CBD and consequently to the inhibition of the proliferative and invasive phenotype of human breast cancer cells. Then, using the mouse 4T1 mammary tumor cell line and the ranksum test, two different syngeneic models of tumor metastasis to the lungs were chosen to determine whether treatment with CBD would reduce metastasis in vivo. We show that CBD inhibits human breast cancer cell proliferation and invasion through differential modulation of the extracellular signal-regulated kinase (ERK) and reactive oxygen species (ROS) pathways, and that both pathways lead to down-regulation of Id-1 expression. Moreover, we demonstrate that CBD up-regulates the pro-differentiation factor, Id-2. Using immune competent mice, we then show that treatment with CBD significantly reduces primary tumor mass as well as the size and number of lung metastatic foci in two models of metastasis. Our data demonstrate the efficacy of CBD in pre-clinical models of breast cancer. The results have the potential to lead to the development of novel non-toxic compounds for the treatment of breast cancer metastasis, and the information gained from these experiments broaden our knowledge of both Id-1 and cannabinoid biology as it pertains to cancer progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859676      PMCID: PMC3410650          DOI: 10.1007/s10549-010-1177-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  46 in total

Review 1.  CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.

Authors:  Sean D McAllister; Michelle Glass
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

2.  Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.

Authors:  Fong Ming Mo; László Offertáler; George Kunos
Journal:  Eur J Pharmacol       Date:  2004-04-05       Impact factor: 4.432

3.  Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Authors:  Alessia Ligresti; Aniello Schiano Moriello; Katarzyna Starowicz; Isabel Matias; Simona Pisanti; Luciano De Petrocellis; Chiara Laezza; Giuseppe Portella; Maurizio Bifulco; Vincenzo Di Marzo
Journal:  J Pharmacol Exp Ther       Date:  2006-05-25       Impact factor: 4.030

Review 4.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

5.  Rap1 mediates sustained MAP kinase activation induced by nerve growth factor.

Authors:  R D York; H Yao; T Dillon; C L Ellig; S P Eckert; E W McCleskey; P J Stork
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

6.  Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059.

Authors:  S Mohr; T S McCormick; E G Lapetina
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

7.  A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.

Authors:  C Q Lin; J Singh; K Murata; Y Itahana; S Parrinello; S H Liang; C E Gillett; J Campisi; P Y Desprez
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

8.  Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis.

Authors:  Sylvia Fong; Yoko Itahana; Tomoki Sumida; Jarnail Singh; Jean-Philippe Coppe; Yong Liu; Peter C Richards; James L Bennington; Nancy M Lee; Robert J Debs; Pierre-Yves Desprez
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

9.  Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization.

Authors:  A J Hiltunen; T U Järbe; K Wängdahl
Journal:  Pharmacol Biochem Behav       Date:  1988-07       Impact factor: 3.533

10.  Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention.

Authors:  S Braun; N Harbeck
Journal:  Expert Rev Mol Med       Date:  2001-09-06       Impact factor: 5.600

View more
  73 in total

1.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Authors:  Mohamad Elbaz; Mohd W Nasser; Janani Ravi; Nissar A Wani; Dinesh K Ahirwar; Helong Zhao; Steve Oghumu; Abhay R Satoskar; Konstantin Shilo; William E Carson; Ramesh K Ganju
Journal:  Mol Oncol       Date:  2015-01-19       Impact factor: 6.603

3.  Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Zhengduo Yang; Christopher Wild; Na Ye; Corbin D Ester; Ailian Xiong; Mark A White; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2013-10-31       Impact factor: 7.446

4.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Authors:  Sara Jane Ward; Sean D McAllister; Rumi Kawamura; Ryuchi Murase; Harshini Neelakantan; Ellen A Walker
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Physiological intestinal oxygen modulates the Caco-2 cell model and increases sensitivity to the phytocannabinoid cannabidiol.

Authors:  Tara Macpherson; Jane A Armstrong; David N Criddle; Karen L Wright
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-01-24       Impact factor: 2.416

Review 7.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 8.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

9.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

10.  Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Authors:  Liliana Soroceanu; Ryuichi Murase; Chandani Limbad; Eric Singer; Juanita Allison; Isabel Adrados; Rumi Kawamura; Arash Pakdel; Yayoi Fukuyo; Daniel Nguyen; Sabeena Khan; Robert Arauz; Garret L Yount; Dan H Moore; Pierre-Yves Desprez; Sean D McAllister
Journal:  Cancer Res       Date:  2012-12-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.